RÉSUMÉ
In an effort to develop new and effective therapeutic agents for Alzheimer's disease, a series of hydrazone derivatives bearing piperidine rings have been designed and synthesized. The chemical structures of the compounds were characterized by various spectroscopic techniques. In vitro antioxidant and cholinesterase activities of the compounds were evaluated. Among the compounds, N12 exhibited the most antioxidant activity in all methods (CUPRAC, FRAP, DPPH, ABTS). In vitro acetylcholinesterase (AChE) activity results of the compounds showed good IC50 values between 14.124 ± 0.084 and 49.680 ± 0.110 µM were obtained (IC50 = 38.842 ± 0.053 µM for Donepezil). Among the compounds, N7 and N6 are much more effective derivatives than the standard compound donepezil with IC50 values of 14.124 ± 0.084 and 17.968 ± 0.072 µM, respectively. In vitro, butyrylcholinesterase (BChE) inhibition values of the compounds were between 13.505 ± 0.025 and 52.230 ± 0.027 µm. Among the compounds, N6 has the highest BChE inhibition with an IC50 value of 13.505 µm in the series. The cytotoxicity and AChE inhibitory activity of the compounds on SH-SY5Y cell lines were also evaluated. Kinetic studies were also performed to determine the behavior of the compounds as competitive or noncompetitive inhibitors. The binding modes of N6, which was determined to be highly effective according to in vitro analyses, with AChE and BChE were investigated using molecular docking studies, and the stability of the complexes was determined by molecular dynamics simulations. These findings indicated that AChE and BChE enzymes maintained their overall structural stability and compactness during interactions with compound N6.
Sujet(s)
Acetylcholinesterase , Butyrylcholine esterase , Anticholinestérasiques , Conception de médicament , Hydrazones , Simulation de docking moléculaire , Pipéridines , Anticholinestérasiques/pharmacologie , Anticholinestérasiques/synthèse chimique , Anticholinestérasiques/composition chimique , Hydrazones/pharmacologie , Hydrazones/synthèse chimique , Hydrazones/composition chimique , Pipéridines/pharmacologie , Pipéridines/composition chimique , Pipéridines/synthèse chimique , Butyrylcholine esterase/métabolisme , Acetylcholinesterase/métabolisme , Humains , Antioxydants/pharmacologie , Antioxydants/synthèse chimique , Antioxydants/composition chimique , Relation structure-activité , Modèles moléculairesRÉSUMÉ
In this paper, we present the synthesis and characterization of two known sulfonyl hydrazides (1 and 2) and their new sulfonyl hydrazone derivatives (9-20), as well as in vitro and in silico investigations of their cytotoxic properties against human lung (A549) and human breast (MCF-7) cancer cell lines. The target compounds (9-20) obtained in high yields were synthesized for the first time by a multi-step reaction, and their structures were confirmed by elemental analysis and various spectral techniques, including FT-IR, 1H-, and 13C-NMR. The antiproliferative profiles of these compounds (1, 2, and 9-20) in this study were determined at concentrations of 200, 100, 50, and 25 µM against selected cancer cell lines for 72 h using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method. Except for compounds 1 and 2, other compounds (9-20) demonstrated cytotoxic activity at concentrations lower than 200 µM. The newly synthesized compounds (9-20) demonstrated antiproliferative activities at a micromolar level, with IC50 values in the range of 29.59-176.70 µM for the A549 cell line and 27.70-170.30 µM for the MCF-7 cell line. Among these compounds, compound 15 (IC50 = 29.59 µM against A549 cell line and IC50 = 27.70 µM against MCF-7 cell line) showed the highest cytotoxic activity against these two cancer cell lines compared to the reference drug cisplatin (IC50 = 22.42 µM against A549 cell line and IC50 = 18.01 µM against MCF-7 cell line). From docking simulations, to establish a plausible binding mode of compounds, we noticed that compound 15 demonstrated the highest affinity (-6.8508 kcal/mol) for estrogen receptor-beta (ERbeta) compared to others, suggesting promising ERbeta binding potential. Most compounds followed Lipinski's rule of five, with acceptable logP values. Additionally, all had mixed gastrointestinal absorption and limited blood-brain barrier permeability. Overall, our study proposed new sulfonyl hydrazones as a potential class of anticancer agents.
Sujet(s)
Antinéoplasiques , Prolifération cellulaire , Conception de médicament , Hydrazones , Simulation de docking moléculaire , Humains , Hydrazones/composition chimique , Hydrazones/pharmacologie , Hydrazones/synthèse chimique , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Antinéoplasiques/synthèse chimique , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cellules MCF-7 , Cellules A549 , Relation structure-activité , Tests de criblage d'agents antitumoraux , Structure moléculaire , Lignée cellulaire tumorale , Esters/composition chimique , Esters/pharmacologieRÉSUMÉ
In our ongoing work to create potential antifungal agents, we synthesized and tested a group of C1-substituted acylhydrazone ß-carboline analogues 9a-o and 10a-o for their effectiveness against Valsa mali, Fusarium solani, Fusarium oxysporum, and Fusarium graminearum. Their compositions were analyzed using different spectral techniques, such as 1H/13C NMR and HRMS, with the structure of 9l being additionally confirmed through X-ray diffraction. The antifungal evaluation showed that, among all the target ß-carboline analogues, compounds 9n and 9o exhibited more promising and broad-spectrum antifungal activity than the commercial pesticide hymexazol. Several intriguing findings regarding structure-activity relationships (SARs) were examined. In addition, the cytotoxicity test showed that these acylhydrazone ß-carboline analogues with C1 substitutions exhibit a preference for fungi, with minimal harm to healthy cells (LO2). The reported findings provide insights into the development of ß-carboline analogues as new potential antifungal agents.
Sujet(s)
Antifongiques , Carbolines , Fusarium , Hydrazones , Tests de sensibilité microbienne , Carbolines/composition chimique , Carbolines/pharmacologie , Carbolines/synthèse chimique , Antifongiques/pharmacologie , Antifongiques/synthèse chimique , Antifongiques/composition chimique , Relation structure-activité , Fusarium/effets des médicaments et des substances chimiques , Hydrazones/pharmacologie , Hydrazones/composition chimique , Hydrazones/synthèse chimique , Structure moléculaire , HumainsRÉSUMÉ
The data on the synthesis of N-aminomorpholine hydrazones are presented. It is shown that the interaction of N-aminomorpholine with functionally substituted benzaldehydes and 4-pyridinaldehyde in isopropyl alcohol leads to the formation of corresponding hydrazones. The structure of the synthesized compounds was studied by 1H and 13C NMR spectroscopy methods, including the COSY (1H-1H), HMQC (1H-13C) and HMBC (1H-13C) methodologies. The values of chemical shifts, multiplicity, and integral intensity of 1H and 13C signals in one-dimensional NMR spectra were determined. The COSY (1H-1H), HMQC (1H-13C), and HMBC (1H-13C) results revealed homo- and heteronuclear interactions, confirming the structure of the studied compounds. The antiviral, cytotoxic, and antimicrobial activity of some synthesized hydrazones were investigated. It is shown that 2-((morpholinoimino)methyl)benzoic acid has a pronounced viral inhibitory property, comparable in its activity to commercial drugs Tamiflu and Remantadine. A docking study was performed using the influenza virus protein models (1930 Swine H1 Hemagglutinin and Neuraminidase of 1918 H1N1 strain). The potential binding sites that are complementary with 2-((morpholinoimino)methyl)benzoic acid were found.
Sujet(s)
Hydrazones , Simulation de docking moléculaire , Morpholines , Hydrazones/composition chimique , Hydrazones/pharmacologie , Hydrazones/synthèse chimique , Morpholines/composition chimique , Morpholines/pharmacologie , Morpholines/synthèse chimique , Humains , Antiviraux/pharmacologie , Antiviraux/composition chimique , Antiviraux/synthèse chimique , Animaux , Relation structure-activité , Tests de sensibilité microbienne , Structure moléculaireRÉSUMÉ
Piperazine is an important functional unit of many clinically approved drugs, including chemotherapeutic agents. In the current study, methyl piperazine was incorporated and eight salicylaldehyde-derived piperazine-functionalized hydrazone ONN-donor ligands (L) and their Pt(II) complexes (L-PtCl) were prepared. The structures of all these ligands (L1-L8) and Pt(II) complexes (C1-C8) were determined using 1H and 13C NMR, UV-vis, FT-IR and HR-ESI MS analyses, whereas the structures of C1, C5, C6, C7 and C8 were determined in the solid state using single crystal X-ray diffraction analysis. Solution state stabilities of C3, C4, C5 and C6 were determined via time-dependent UV-vis spectroscopy. All these complexes (C1-C8) were studied for their anticancer effect in pancreatic ductal adenocarcinoma cells, including BxPC3, MIAPaCa-2 and PANC1 cells. C1-C8 displayed a potential cytotoxic effect in all these cancer cells, among which C5, C6 and C8 showed the strongest inhibitory effect in comparison with standard chemotherapeutic agents, including 5-fluorouracil (5-FU), cisplatin (CP), oxaliplatin and doxorubicin (DOX). C5, C6 and C8 suppressed the growth of pancreatic cancer cells in a dose-dependent manner. Moreover, C5, C6 and C8 inhibited clonogenic potential and invasion ability and induced apoptosis in PANC1 cells. Importantly, C5, C6 and C8 synergized the anticancer effect with PARP inhibitors, including olaparib, veliparib and niraparib, in pancreatic cancer cells, thus suggesting an important role of C5, C6 and C8 in induction of apoptosis in combination with PARP inhibitors. C5 combined with PARP inhibitors induced caspase3/7 activity and suppressed ATP production. Mechanistically, C5, C6 and C8 inhibited EZH2 protein expression to suppress EZH2-dependent tumorigenesis. Overall, these results highlighted the importance of these piperazine-functionalized Pt(II) complexes as potential anticancer agents to suppress pancreatic ductal adenocarcinoma tumorigenesis by targeting the EZH2-dependent pathway.
Sujet(s)
Aldéhydes , Antinéoplasiques , Apoptose , Protéine-2 homologue de l'activateur de Zeste , Hydrazones , Tumeurs du pancréas , Pipérazine , Inhibiteurs de poly(ADP-ribose) polymérases , Apoptose/effets des médicaments et des substances chimiques , Humains , Hydrazones/composition chimique , Hydrazones/pharmacologie , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Antinéoplasiques/synthèse chimique , Tumeurs du pancréas/traitement médicamenteux , Tumeurs du pancréas/anatomopathologie , Tumeurs du pancréas/métabolisme , Ligands , Aldéhydes/composition chimique , Aldéhydes/pharmacologie , Pipérazine/composition chimique , Pipérazine/pharmacologie , Inhibiteurs de poly(ADP-ribose) polymérases/pharmacologie , Inhibiteurs de poly(ADP-ribose) polymérases/composition chimique , Inhibiteurs de poly(ADP-ribose) polymérases/synthèse chimique , Protéine-2 homologue de l'activateur de Zeste/antagonistes et inhibiteurs , Protéine-2 homologue de l'activateur de Zeste/métabolisme , Lignée cellulaire tumorale , Carcinome du canal pancréatique/traitement médicamenteux , Carcinome du canal pancréatique/anatomopathologie , Carcinome du canal pancréatique/métabolisme , Prolifération cellulaire/effets des médicaments et des substances chimiques , Pipérazines/pharmacologie , Pipérazines/composition chimique , Tests de criblage d'agents antitumoraux , Synergie des médicaments , Complexes de coordination/pharmacologie , Complexes de coordination/composition chimique , Complexes de coordination/synthèse chimique , Composés organiques du platine/pharmacologie , Composés organiques du platine/composition chimique , Composés organiques du platine/synthèse chimiqueRÉSUMÉ
Hydrazones display an interesting profile of biological activities, which includes mainly antimicrobial and antiproliferative properties. Hydrazones also play an important role in the synthesis of heterocyclic rings and in coordination chemistry. Currently, the synthesis of complexes of hydrazones with transition metals is quite frequently reported in the scientific literature. The interest in this topic is largely due to diverse biological activities of the metal complexes of hydrazones that in some cases are much more effective than hydrazones themselves. This review focuses on the complexes of hydrazones with transition metals which display antibacterial, antitubercular, antifungal and anticancer activities. In the following subchapters devoted to a given activity, an attempt has been made to present the most active complexes of hydrazones, their trends in their activity and application in medicinal chemistry. The paper presents the literature data from 2009 to 2023. This review constitutes a useful guide for the researchers who intend to synthesize and investigate complexes of hydrazones in terms of their antimicrobial and anticancer activities.
Sujet(s)
Anti-infectieux , Antinéoplasiques , Complexes de coordination , Hydrazones , Éléments de transition , Hydrazones/composition chimique , Hydrazones/pharmacologie , Hydrazones/synthèse chimique , Antinéoplasiques/composition chimique , Antinéoplasiques/pharmacologie , Antinéoplasiques/synthèse chimique , Éléments de transition/composition chimique , Éléments de transition/pharmacologie , Complexes de coordination/composition chimique , Complexes de coordination/pharmacologie , Complexes de coordination/synthèse chimique , Humains , Anti-infectieux/pharmacologie , Anti-infectieux/composition chimique , Anti-infectieux/synthèse chimique , Tumeurs/traitement médicamenteuxRÉSUMÉ
Adult neurogenesis involves the generation of functional neurons from neural progenitor cells, which have the potential to complement and restore damaged neurons and neural circuits. Therefore, the development of drugs that stimulate neurogenesis represents a promising strategy in stem cell therapy and neural regeneration, greatly facilitating the reconstruction of neural circuits in cases of neurodegeneration and brain injury. Our study reveals that compound A5, previously designed and synthesized by our team, exhibits remarkable neuritogenic activities, effectively inducing neurogenesis in neural stem/progenitor cells (NSPCs). Subsequently, transcriptome analysis using high-throughput Illumina RNA-seq technology was performed to further elucidate the underlying molecular mechanisms by which Compound A5 promotes neurogenesis. Notably, comparative transcriptome analysis showed that the up-regulated genes were mainly associated with neurogenesis, and the down-regulated genes were mainly concerned with cell cycle progression. Furthermore, we confirmed that Compound A5 significantly affected the expression of transcription factors related to neurogenesis and cell cycle regulatory proteins. Collectively, these findings identify a new compound with neurogenic activity and may provide insights into drug discovery for neural repair and regeneration.
Sujet(s)
Cycle cellulaire , Hydrazones , Cellules souches neurales , Neurogenèse , Neurogenèse/effets des médicaments et des substances chimiques , Cellules souches neurales/effets des médicaments et des substances chimiques , Cellules souches neurales/métabolisme , Cellules souches neurales/cytologie , Animaux , Cycle cellulaire/effets des médicaments et des substances chimiques , Hydrazones/pharmacologie , Hydrazones/composition chimique , Analyse de profil d'expression de gènes , Régulation positive/effets des médicaments et des substances chimiques , Souris , Transcriptome , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Différenciation cellulaire/effets des médicaments et des substances chimiquesRÉSUMÉ
In this study, we present the design, synthesis, and cytotoxic evaluation of a series of benzimidazole N-acylhydrazones against strains of T. cruzi (Y and Tulahuen) and Leishmania species (L. amazonensis and L. infantum). Compound (E)-N'-((5-Nitrofuran-2-yl)methylene)-1H-benzo[d]imidazole-2-carbohydrazide demonstrated significant activity against both trypomastigote and amastigote forms (Tulahuen strain), with an IC50/120 h of 0.033 µM and a selectivity index (SI) of 7680. This represents a potency 46 times greater than that of benznidazole (IC50/120 h = 1.520 µM, SI = 1390). Another compound (E)-N'-(2-Hydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide showed promising activity against both trypomastigote and amastigote forms (Tulahuen strain), with an IC50/120 h of 3.600 µM and an SI of 14.70. However, its efficacy against L. infantum and L. amazonensis was comparatively lower. These findings provide valuable insights for the development of more effective treatments against Trypanosoma cruzi.
Sujet(s)
Benzimidazoles , Hydrazones , Leishmania infantum , Trypanosoma cruzi , Trypanosoma cruzi/effets des médicaments et des substances chimiques , Hydrazones/pharmacologie , Hydrazones/composition chimique , Hydrazones/synthèse chimique , Relation structure-activité , Leishmania infantum/effets des médicaments et des substances chimiques , Benzimidazoles/pharmacologie , Benzimidazoles/composition chimique , Benzimidazoles/synthèse chimique , Structure moléculaire , Tests de sensibilité parasitaire , Relation dose-effet des médicaments , Leishmania/effets des médicaments et des substances chimiques , Trypanocides/pharmacologie , Trypanocides/synthèse chimique , Trypanocides/composition chimique , Antiprotozoaires/pharmacologie , Antiprotozoaires/synthèse chimique , Antiprotozoaires/composition chimique , AnimauxRÉSUMÉ
Heterocyclic compounds, particularly those containing azole rings, have shown extensive biological activity, including anticancer, antibacterial, and antifungal properties. Among these, the imidazole ring stands out due to its diverse therapeutic potential. In the presented study, we designed and synthesized a series of imidazole derivatives to identify compounds with high biological potential. We focused on two groups: thiosemicarbazide derivatives and hydrazone derivatives. We synthesized these compounds using conventional methods and confirmed their structures via nuclear magnetic resonance spectroscopy (NMR), MS, and elemental analysis, and then assessed their antibacterial and antifungal activities in vitro using the broth microdilution method against Gram-positive and Gram-negative bacteria, as well as Candida spp. strains. Our results showed that thiosemicarbazide derivatives exhibited varied activity against Gram-positive bacteria, with MIC values ranging from 31.25 to 1000 µg/mL. The hydrazone derivatives, however, did not display significant antibacterial activity. These findings suggest that structural modifications can significantly influence the antimicrobial efficacy of imidazole derivatives, highlighting the potential of thiosemicarbazide derivatives as promising candidates for further development in antibacterial therapies. Additionally, the cytotoxic activity against four cancer cell lines was evaluated. Two derivatives of hydrazide-hydrazone showed moderate anticancer activity.
Sujet(s)
Antibactériens , Antifongiques , Antinéoplasiques , Bactéries à Gram positif , Tests de sensibilité microbienne , Humains , Antibactériens/pharmacologie , Antibactériens/synthèse chimique , Antibactériens/composition chimique , Antinéoplasiques/pharmacologie , Antinéoplasiques/synthèse chimique , Antinéoplasiques/composition chimique , Antifongiques/pharmacologie , Antifongiques/synthèse chimique , Antifongiques/composition chimique , Bactéries à Gram positif/effets des médicaments et des substances chimiques , Nitroimidazoles/pharmacologie , Nitroimidazoles/composition chimique , Nitroimidazoles/synthèse chimique , Lignée cellulaire tumorale , Bactéries à Gram négatif/effets des médicaments et des substances chimiques , Relation structure-activité , Semicarbazides/composition chimique , Semicarbazides/pharmacologie , Semicarbazides/synthèse chimique , Hydrazones/composition chimique , Hydrazones/pharmacologie , Hydrazones/synthèse chimique , Candida/effets des médicaments et des substances chimiques , Structure moléculaireRÉSUMÉ
Leishmaniasis is a disease caused by protozoa Leishmania spp., considered as a significant and urgent public health problem mainly in developing countries. In the absence of an effective vaccine, the treatment of infected people is one of the most commonly prophylactic measures used to control this disease. However, the therapeutic arsenal is reduced to a few drugs, with serious side effects and variability in efficacy. Attempting to this problem, in this work, a series of benzothiazole derivatives was synthetized and assayed against promastigotes and intracellular amastigotes of L. amazonensis, as well as the toxicity on macrophages. In addition, studies about the mechanism of action were also performed. Among the synthesized molecules, the substitution at position 4 of the aromatic ring appears to be critical for activity. The best compound exhibited IC50 values of 28.86 and 7.70 µM, against promastigotes and amastigotes of L. amazonensis, respectively, being more active than miltefosine, used as reference drug. The in silico analysis of physicochemical and pharmacokinetic (ADMET) properties of this compound suggested a good profile of oral bioavailability and safety. In conclusion, the strategy of using benzothiazole nucleous in the search for new antileishmanial agents was advantageous and preliminar data provide information about the mechanism of action as well as in silico parameters suggest a good profile for preclinical studies.
Sujet(s)
Antiprotozoaires , Benzothiazoles , Hydrazones , Leishmania , Benzothiazoles/composition chimique , Benzothiazoles/pharmacologie , Benzothiazoles/synthèse chimique , Antiprotozoaires/pharmacologie , Antiprotozoaires/composition chimique , Antiprotozoaires/synthèse chimique , Animaux , Hydrazones/composition chimique , Hydrazones/pharmacologie , Hydrazones/synthèse chimique , Souris , Leishmania/effets des médicaments et des substances chimiques , Macrophages/effets des médicaments et des substances chimiques , Macrophages/parasitologie , Relation structure-activité , HumainsRÉSUMÉ
The discovery of effective and safe antiobesity agents remains a challenging yet promising field. Our previous studies identified Bouchardatine derivatives as potential antiobesity agents. However, the 8a-aldehyde moiety rendered them unsuitable for drug development. In this study, we designed two series of novel derivatives to modify this structural feature. Through a structure-activity relationship study, we elucidated the role of the 8a-aldehyde group in toxicity induction. We identified compound 14d, featuring an 8a-N-acylhydrazone moiety, which exhibited significant lipid-lowering activity and reduced toxicity. Compound 14d shares a similar lipid-lowering mechanism with our lead compound 3, but demonstrates improved pharmacokinetic properties and safety profile. Both oral and injectable administration of 14d significantly reduced body weight gain and ameliorated metabolic syndrome in diet-induced obese mice. Our findings identify 14d as a promising antiobesity agent and highlight the potential of substituting the aldehyde group with an N-acylhydrazone to enhance drug-like properties.
Sujet(s)
Aldéhydes , Agents antiobésité , Hydrazones , Obésité , Animaux , Agents antiobésité/pharmacologie , Agents antiobésité/synthèse chimique , Agents antiobésité/pharmacocinétique , Agents antiobésité/usage thérapeutique , Agents antiobésité/composition chimique , Hydrazones/pharmacologie , Hydrazones/composition chimique , Hydrazones/synthèse chimique , Hydrazones/pharmacocinétique , Hydrazones/usage thérapeutique , Souris , Relation structure-activité , Aldéhydes/composition chimique , Mâle , Obésité/traitement médicamenteux , Souris de lignée C57BL , Alimentation riche en graisse/effets indésirables , Humains , Souris obèse , Structure moléculaireRÉSUMÉ
In this paper, three different Zn(II) complexes with (E)-2-(2-(1-(6-bromopyridin-2-yl)ethylidene)hydrazinyl)-N,N,N-trimethyl-2-oxoethan-1-aminium chloride (HLCl) have been synthesized and characterized by single crystal X-ray diffraction, elemental analysis, IR and NMR spectroscopy. All complexes are mononuclear, with the ligand (L) coordinated in a deprotonated formally neutral zwitterionic form via NNO donor set atoms. Complex 1 forms an octahedral geometry with the composition [ZnL2](BF4)2, while complexes 2 [ZnL(NCO)2] and 3 [ZnL(N3)2] form penta-coordinated geometry. Density functional theory (DFT) calculations were performed to enhance our understanding of the structures of the synthesized complexes and the cytotoxic activity of the complexes was tested against five human cancer cell lines (HeLa, A549, MDA-MB-231, K562, LS 174T) and normal human fibroblasts MRC-5. Additionally, antibacterial and antifungal activity of these complexes was tested against a panel of Gram-negative and Gram-positive bacteria, two fungal strains, and a yeast strain. It is noteworthy that all three complexes show selective antifungal activity comparable to that of amphotericin B. Molecular docking analysis predicted that geranylgeranyl pyrophosphate synthase, an enzyme essential for sterol biosynthesis, is the most likely target for inhibition by the tested complexes.
Sujet(s)
Antibactériens , Antifongiques , Antinéoplasiques , Complexes de coordination , Théorie de la fonctionnelle de la densité , Hydrazones , Tests de sensibilité microbienne , Zinc , Humains , Hydrazones/composition chimique , Hydrazones/pharmacologie , Hydrazones/synthèse chimique , Zinc/composition chimique , Zinc/pharmacologie , Complexes de coordination/pharmacologie , Complexes de coordination/composition chimique , Complexes de coordination/synthèse chimique , Antibactériens/pharmacologie , Antibactériens/composition chimique , Antibactériens/synthèse chimique , Antifongiques/pharmacologie , Antifongiques/composition chimique , Antifongiques/synthèse chimique , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Antinéoplasiques/synthèse chimique , Lignée cellulaire tumorale , Structure moléculaire , Simulation de docking moléculaire , Tests de criblage d'agents antitumoraux , Bactéries à Gram négatif/effets des médicaments et des substances chimiques , Bactéries à Gram positif/effets des médicaments et des substances chimiques , Modèles moléculaires , Champignons/effets des médicaments et des substances chimiques , Relation structure-activitéRÉSUMÉ
Efforts in researching the efficient anti-tumor properties of three novel arene ruthenium(II) complexes incorporating thiophene-based aroylhydrazone ligands have been undertaken. The complexes' elemental composition was [(η6-p-cymene)Ru(L)Cl]. They were comprehensively characterized through elemental and spectroscopic analyses (FT-IR, UV-vis, NMR, and HR-MS). Single crystal X-ray diffraction studies revealed a pseudo-octahedral geometry with bidentate coordination of the ligands in a representative complex. The in vitro assessment of the complexes' cancer cell growth inhibition was conducted using the MTT assay against A549 (human lung carcinoma), HeLa (human cervical carcinoma), HuH-7 (hepatocellular carcinoma), and NIH-3T3 (mouse fibroblast non-cancerous cell line). Results indicated significant cytotoxicity across all cancer cell lines, with IC50 concentrations of complex 2 being 6.8 µM for A549, 11.6 µM for HeLa, and 9.4 µM for HuH-7, compared to cisplatin with IC50 values of 18.9 µM, 17.68 µM, and 24 µM respectively. Notably, complex 2 demonstrated particularly promising cytotoxicity against all tested cancerous cell lines. Fluorescent staining analysis such as acridine orange/ethidium bromide (AO-EB) and HOECHST 33342 revealed cell death mechanisms involving membrane disintegration and nuclear condensation following treatment with complex 2. Further studies were conducted to measure reactive oxygen species (ROS) levels using the dichlorodihydrofluorescein diacetate (DCFH-DA) assay, and mitochondrial membrane potential (MMP) was assessed using the JC-1 dye assay. These studies demonstrated that complex 2 increased ROS levels, decreased membrane potential, and promoted mitochondrial dysfunction-mediated cell death pathways. Additionally, flow cytometry analysis, utilizing dual staining of Annexin V-FITC and propidium iodide (PI), was employed to quantitatively study apoptosis induction.
Sujet(s)
Antinéoplasiques , Apoptose , Prolifération cellulaire , Complexes de coordination , Tests de criblage d'agents antitumoraux , Hydrazones , Ruthénium , Thiophènes , Humains , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Antinéoplasiques/synthèse chimique , Ruthénium/composition chimique , Ruthénium/pharmacologie , Complexes de coordination/pharmacologie , Complexes de coordination/composition chimique , Complexes de coordination/synthèse chimique , Prolifération cellulaire/effets des médicaments et des substances chimiques , Animaux , Souris , Thiophènes/composition chimique , Thiophènes/pharmacologie , Hydrazones/composition chimique , Hydrazones/pharmacologie , Apoptose/effets des médicaments et des substances chimiques , Espèces réactives de l'oxygène/métabolisme , Potentiel de membrane mitochondriale/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Structure moléculaire , Cellules NIH 3T3 , Relation structure-activitéRÉSUMÉ
In search of small molecules for targeted therapy of non-small cell lung carcinoma (NSCLC), an efficient four-step synthetic route was followed for the synthesis of new imidazothiazole-hydrazone hybrids, which were assessed for their cytotoxic effects on human lung adenocarcinoma (A549) and human lung fibroblast (CCD-19Lu) cells. Among them, compounds 4, 6, 13, 16, 17 and 21 exhibited selective cytotoxic activity against A549 cell line. In vitro mechanistic studies were performed to assess their effects on apoptosis, caspase-3, cell cycle, EGFR and Akt in A549 cells. Compounds 6, 16, 17 and 21 promoted apoptotic cell death more than erlotinib. According to the in vitro data, it is quite clear that compound 6 promotes apoptosis through caspase-3 activation and arrests the cell cycle at the G0/G1 phase in A549 cells. Compounds 16 and 17 arrested the cell cycle at the S phase, whereas compounds 4, 13 and 21 caused the cell cycle arrest at the G2/M phase. The most effective EGFR inhibitor in this series was found as compound 13, followed by compounds 17 and 16. Furthermore, Akt inhibitory effects of compounds 16 and 17 in A549 cells were close to that of GSK690693. In particular, it can be concluded that the cytotoxic and apoptotic effects of compounds 16 and 17 are associated with their inhibitory effects on both EGFR and Akt. Molecular docking studies suggest that compounds 16 and 17 interact with crucial amino acid residues in the binding sites of human EGFR (PDB ID: 1M17) and Akt2 (PDB ID: 3D0E). Based on the in silico data, both compounds are predicted to possess favorable oral bioavailability and drug-likeness. Further studies are required to benefit from these compounds as anticancer agents for targeted therapy of NSCLC.
Sujet(s)
Antinéoplasiques , Apoptose , Carcinome pulmonaire non à petites cellules , Prolifération cellulaire , Conception de médicament , Tests de criblage d'agents antitumoraux , Récepteurs ErbB , Hydrazones , Tumeurs du poumon , Inhibiteurs de protéines kinases , Protéines proto-oncogènes c-akt , Humains , Récepteurs ErbB/antagonistes et inhibiteurs , Récepteurs ErbB/métabolisme , Protéines proto-oncogènes c-akt/métabolisme , Protéines proto-oncogènes c-akt/antagonistes et inhibiteurs , Carcinome pulmonaire non à petites cellules/traitement médicamenteux , Carcinome pulmonaire non à petites cellules/anatomopathologie , Carcinome pulmonaire non à petites cellules/métabolisme , Antinéoplasiques/pharmacologie , Antinéoplasiques/synthèse chimique , Antinéoplasiques/composition chimique , Tumeurs du poumon/traitement médicamenteux , Tumeurs du poumon/anatomopathologie , Tumeurs du poumon/métabolisme , Inhibiteurs de protéines kinases/pharmacologie , Inhibiteurs de protéines kinases/synthèse chimique , Inhibiteurs de protéines kinases/composition chimique , Hydrazones/pharmacologie , Hydrazones/composition chimique , Hydrazones/synthèse chimique , Relation structure-activité , Apoptose/effets des médicaments et des substances chimiques , Structure moléculaire , Prolifération cellulaire/effets des médicaments et des substances chimiques , Thiazoles/composition chimique , Thiazoles/pharmacologie , Thiazoles/synthèse chimique , Imidazoles/pharmacologie , Imidazoles/composition chimique , Imidazoles/synthèse chimique , Simulation de docking moléculaire , Relation dose-effet des médicaments , Cycle cellulaire/effets des médicaments et des substances chimiquesRÉSUMÉ
BACKGROUND: The upsurge of antimicrobial resistance demands innovative strategies to fight bacterial infections. With traditional antibiotics becoming less effective, anti-virulence agents or pathoblockers, arise as an alternative approach that seeks to disarm pathogens without affecting their viability, thereby reducing selective pressure for the emergence of resistance mechanisms. OBJECTIVES: To elucidate the mechanism of action of compound N'-(thiophen-2-ylmethylene)benzohydrazide (A16B1), a potent synthetic hydrazone inhibitor against the Salmonella PhoP/PhoQ system, essential for virulence. MATERIALS AND METHODS: The measurement of the activity of PhoP/PhoQ-dependent and -independent reporter genes was used to evaluate the specificity of A16B1 to the PhoP regulon. Autokinase activity assays with either the native or truncated versions of PhoQ were used to dissect the A16B1 mechanism of action. The effect of A16B1 on Salmonella intramacrophage replication was assessed using the gentamicin protection assay. The checkerboard assay approach was used to analyse potentiation effects of colistin with the hydrazone. The Galleria mellonella infection model was chosen to evaluate A16B1 as an in vivo therapy against Salmonella. RESULTS: A16B1 repressed the Salmonella PhoP/PhoQ system activity, specifically targeting PhoQ within the second transmembrane region. A16B1 demonstrates synergy with the antimicrobial peptide colistin, reduces the intramacrophage proliferation of Salmonella without being cytotoxic and enhances the survival of G. mellonella larvae systemically infected with Salmonella. CONCLUSIONS: A16B1 selectively inhibits the activity of the Salmonella PhoP/PhoQ system through a novel inhibitory mechanism, representing a promising synthetic hydrazone compound with the potential to function as a Salmonella pathoblocker. This offers innovative prospects for combating Salmonella infections while mitigating the risk of antimicrobial resistance emergence.
Sujet(s)
Antibactériens , Protéines bactériennes , Salmonelloses , Animaux , Protéines bactériennes/antagonistes et inhibiteurs , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Salmonelloses/traitement médicamenteux , Salmonelloses/microbiologie , Papillons de nuit/microbiologie , Modèles animaux de maladie humaine , Salmonella typhimurium/effets des médicaments et des substances chimiques , Salmonella typhimurium/génétique , Colistine/pharmacologie , Tests de sensibilité microbienne , Hydrazones/pharmacologie , Hydrazones/usage thérapeutique , Synergie des médicaments , Virulence/effets des médicaments et des substances chimiques , Histidine kinase/antagonistes et inhibiteurs , Histidine kinase/génétique , Régulation allostérique/effets des médicaments et des substances chimiquesRÉSUMÉ
Hepatocellular carcinoma (HCC) is a significant contributor to cancer-related deaths globally. Systemic therapy is the only treatment option for HCC at an advanced stage, with limited therapeutic response. In this study, we evaluated the antitumor potential of four N-acylhydrazone (NAH) derivatives, namely LASSBio-1909, 1911, 1935, and 1936, on HCC cell lines. We have previously demonstrated that the aforementioned NAH derivatives selectively inhibit histone deacetylase 6 (HDAC6) in lung cancer cells, but their effects on HCC cells have not been explored. Thus, the present study aimed to evaluate the effects of NAH derivatives on the proliferative behavior of HCC cells. LASSBio-1911 was the most cytotoxic compound against HCC cells, however its effects were minimal on normal cells. Our results showed that LASSBio-1911 inhibited HDAC6 in HCC cells leading to cell cycle arrest and decreased cell proliferation. There was also an increase in the frequency of cells in mitosis onset, which was associated with disturbing mitotic spindle formation. These events were accompanied by elevated levels of CDKN1A mRNA, accumulation of CCNB1 protein, and sustained ERK1 phosphorylation. Furthermore, LASSBio-1911 induced DNA damage, resulting in senescence and/or apoptosis. Our findings indicate that selective inhibition of HDAC6 may provide an effective therapeutic strategy for the treatment of advanced HCC, including tumor subtypes with integrated viral genome. Further, in vivo studies are required to validate the antitumor effect of LASSBio-1911 on liver cancer.
Sujet(s)
Antinéoplasiques , Carcinome hépatocellulaire , Prolifération cellulaire , Vieillissement de la cellule , Histone deacetylase 6 , Inhibiteurs de désacétylase d'histone , Hydrazones , Tumeurs du foie , Histone deacetylase 6/antagonistes et inhibiteurs , Humains , Carcinome hépatocellulaire/traitement médicamenteux , Tumeurs du foie/traitement médicamenteux , Prolifération cellulaire/effets des médicaments et des substances chimiques , Hydrazones/pharmacologie , Vieillissement de la cellule/effets des médicaments et des substances chimiques , Inhibiteurs de désacétylase d'histone/pharmacologie , Lignée cellulaire tumorale , Antinéoplasiques/pharmacologie , Inhibiteur p21 de kinase cycline-dépendante/métabolisme , Inhibiteur p21 de kinase cycline-dépendante/génétique , Cycline B1/métabolisme , Cycline B1/génétiqueRÉSUMÉ
In this study, seven isoniazid-hydrazone derivatives (3a-g) were synthesized and their structures elucidated by chromatographic techniques, and then the antiproliferative effects of these compounds on various cancer cells were tested. The advanced anticancer mechanism of the most potent compound was then investigated. Antiproliferative activities of the synthesized compounds were evaluated on human breast cancer MCF-7, lung cancer A-549, colon cancer HT-29, and non-cancerous mouse fibroblast 3T3-L1 cell lines by XTT assay. Flow cytometry analysis were carried out to determine cell cycle distribution, apoptosis, mitochondrial membrane potential, multi-caspase activity, and expression of PI3K/AKT signaling pathway. The XTT results showed that all the title molecules displayed cytotoxic activity at varying strengths in different dose ranges, and among them, the strongest cytotoxic effect and high selectivity were exerted by 3d against MCF-7 cells with the IC50 value of 11.35 µM and selectivity index of 8.65. Flow cytometry results revealed that compound 3d induced apoptosis through mitochondrial membrane disruption and multi-caspase activation in MCF-7 cells. It also inhibited the cell proliferation via inhibition of expression of PI3K/AKT and arrested the cell cycle at G0/G1 phase. In conclusion, all these data disclosed that among the synthesized compounds, 3d is notable for in vivo anticancer studies.
Sujet(s)
Antinéoplasiques , Apoptose , Caspases , Points de contrôle du cycle cellulaire , Prolifération cellulaire , Relation dose-effet des médicaments , Tests de criblage d'agents antitumoraux , Hydrazones , Isoniazide , Mitochondries , Phosphatidylinositol 3-kinases , Protéines proto-oncogènes c-akt , Humains , Protéines proto-oncogènes c-akt/métabolisme , Protéines proto-oncogènes c-akt/antagonistes et inhibiteurs , Apoptose/effets des médicaments et des substances chimiques , Phosphatidylinositol 3-kinases/métabolisme , Prolifération cellulaire/effets des médicaments et des substances chimiques , Hydrazones/pharmacologie , Hydrazones/composition chimique , Hydrazones/synthèse chimique , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Antinéoplasiques/synthèse chimique , Points de contrôle du cycle cellulaire/effets des médicaments et des substances chimiques , Relation structure-activité , Mitochondries/effets des médicaments et des substances chimiques , Mitochondries/métabolisme , Structure moléculaire , Caspases/métabolisme , Isoniazide/pharmacologie , Isoniazide/composition chimique , Inhibiteurs des phosphoinositide-3 kinases/pharmacologie , Inhibiteurs des phosphoinositide-3 kinases/composition chimique , Inhibiteurs des phosphoinositide-3 kinases/synthèse chimique , Souris , AnimauxRÉSUMÉ
Molecular hybridization between structural fragments from the structures of curcumin (1) and resveratrol (2) was used as a designing tool to generate a new N-acyl-cinnamoyl-hydrazone hybrid molecular architecture. Twenty-eight new compounds were synthesized and evaluated for multifunctional activities related to Parkinson's disease (PD), including neuroprotection, antioxidant, metal chelating ability, and Keap1/Nrf2 pathway activation. Compounds 3b (PQM-161) and 3e (PQM-164) were highlighted for their significant antioxidant profile, acting directly as induced free radical stabilizers by DPPH and indirectly by modulating intracellular inhibition of t-BOOH-induced ROS formation in neuronal cells. The mechanism of action was determined as a result of Keap1/Nrf2 pathway activation by both compounds and confirmed by different experiments. Furthermore, compound 3e (PQM-164) exhibited a significant effect on the accumulation of α-synuclein and anti-inflammatory activity, leading to an expressive decrease in gene expression of iNOS, IL-1ß, and TNF-α. Overall, these results highlighted compound 3e as a promising and innovative multifunctional drug prototype candidate for PD treatment.
Sujet(s)
Hydrazones , Neuroprotecteurs , Maladie de Parkinson , Neuroprotecteurs/pharmacologie , Neuroprotecteurs/composition chimique , Neuroprotecteurs/synthèse chimique , Hydrazones/pharmacologie , Hydrazones/composition chimique , Hydrazones/synthèse chimique , Maladie de Parkinson/traitement médicamenteux , Maladie de Parkinson/métabolisme , Humains , Structure moléculaire , Relation structure-activité , Relation dose-effet des médicaments , Conception de médicament , Antioxydants/pharmacologie , Antioxydants/synthèse chimique , Antioxydants/composition chimique , Animaux , Cinnamates/pharmacologie , Cinnamates/composition chimique , Cinnamates/synthèse chimiqueRÉSUMÉ
Wet synthesis approach afforded four new heteroleptic mononuclear neutral diamagnetic oxidovanadium(V) complexes, comprising salicylaldehyde-based 2-furoic acid hydrazones and a flavonol coligand of the general composition [VO(fla)(L-ONO)]. The complexes were comprehensively characterized, including chemical analysis, conductometry, infrared, electronic, and mass spectroscopy, as well as 1D 1H and proton-decoupled 13C(1H) NMR spectroscopy, alongside extensive 2D 1H1H COSY, 1H13C HMQC, and 1H13C HMBC NMR analyses. Additionally, the quantum chemical properties of the complexes were studied using Gaussian at the B3LYP, HF, and M062X levels on the 6-31++g(d,p) basis sets. The interaction of these hydrolytically inert vanadium complexes and the BSA was investigated through spectrofluorimetric titration, synchronous fluorimetry, and FRET analysis in a temperature-dependent manner, providing valuable thermodynamic insights into van der Waals interactions and hydrogen bonding. Molecular docking was conducted to gain further understanding of the specific binding sites of the complexes to BSA. Complex 2, featuring a 5-chloro-substituted salicylaldehyde component of the hydrazone, was extensively examined for its biological activity in vivo. The effects of complex administration on biochemical and hematological parameters were evaluated in both healthy and diabetic Wistar rats, revealing antihyperglycemic activity at millimolar concentration. Furthermore, histopathological analysis and bioaccumulation studies of the complex in the brain, kidneys, and livers of healthy and diabetic rats revealed the potential for further development of vanadium(V) hydrazone complexes as antidiabetic and insulin-mimetic agents.
Sujet(s)
Complexes de coordination , Diabète expérimental , Hydrazones , Hypoglycémiants , Simulation de docking moléculaire , Vanadium , Animaux , Hydrazones/composition chimique , Hydrazones/synthèse chimique , Hydrazones/pharmacologie , Rats , Diabète expérimental/traitement médicamenteux , Hypoglycémiants/composition chimique , Hypoglycémiants/synthèse chimique , Hypoglycémiants/pharmacologie , Complexes de coordination/synthèse chimique , Complexes de coordination/pharmacologie , Complexes de coordination/composition chimique , Vanadium/composition chimique , Flavonols/pharmacologie , Flavonols/composition chimique , Flavonols/synthèse chimique , Mâle , Rat Wistar , Sérumalbumine bovine/composition chimique , Sérumalbumine bovine/métabolisme , AldéhydesRÉSUMÉ
In this study, super-resolution structured illumination microscope (SIM) was used to analyze molecular mechanism of endocytic acidification inhibitors in the SARS-CoV-2 pandemic, such as Chloroquine (CQ), Hydroxychloroquine (HCQ) and Bafilomycin A1 (BafA1). We fluorescently labeled the SARS-CoV-2 RBD and its receptor ACE2 protein with small molecule dyes. Utilizing SIM imaging, the real-time impact of inhibitors (BafA1, CQ, HCQ, Dynasore) on the RBD-ACE2 endocytotic process was dynamically tracked in living cells. Initially, the protein activity of RBD and ACE2 was ensured after being labeled. And then our findings revealed that these inhibitors could inhibit the internalization and degradation of RBD-ACE2 to varying degrees. Among them, 100â nM BafA1 exhibited the most satisfactory endocytotic inhibition (~63.9 %) and protein degradation inhibition (~97.7 %). And it could inhibit the fusion between endocytic vesicles in the living cells. Additionally, Dynasore, a widely recognized dynein inhibitor, also demonstrated cell acidification inhibition effects. Together, these inhibitors collectively hinder SARS-CoV-2 infection by inhibiting both the viral internalization and RNA release. The comprehensive evaluation of pharmacological mechanisms through super-resolution fluorescence imaging has laid a crucial theoretical foundation for the development of potential drugs to treat COVID-19.